Neurocognitive Effects of Electroconvulsive Therapy in Psychiatric Disorders, Mechanism of Action And its Prevention: Review Article

Waheeda Shokat Kassam Kara¹*, Khamis Hassan Bakari², Henry Anselmo Mayala², Bing Shao¹, Mao Jing¹

¹School Of Nursing, Tongji Medical College, Huazhong University Of Science And Technology, Hangkong Road No 13 Hankou, Jiefang Avenue, Wuhan, Hubei Province, 430022, P. R. China.
²Tongji Medical College, Huazhong University Of Science And Technology, Hubei, Wuhan, China

Abstract: Electroconvulsive therapy has been widely used in the treatment of various psychiatric and somatic conditions such as obsessive compulsive disorder, postpartum psychosis, Parkinson’s disease, depression, bipolar disorder and schizophrenia with varying degree of success. Currently, its utilisation has been constrained to limited conditions due to its neurocognitive side effects. Neurocognitive impairment associated with ECT treatment includes slow processing speed, verbal and memory deficits which manifest as post ictal confusion, anterograde and/or retrograde memory amnesia, or long-term subjective memory deficit in few patients. Memory deficits caused by ECT usually last for less than six months after the end of ECT treatment, but there is no impairment of acquisition and retention of new memories. Propofol and liothyronine prevent memory deficits post-ECT treatment through different mechanisms.

Keywords: Electroconvulsive therapy (ECT), calcium/calmodulin-dependant protein kinase IIα (CaMK IIα), Major Depressive Disorder (MDD), Glutamic Acid Decarboxylase 65 (GAD 65)

I. Introduction

In the early 16th century, treatment of mental illness using convulsion was first experimented using camphor oil, followed by seizure-induction by application of electrical current to the human brain which was introduced by the Italians Cerletti and Bini in 1938¹. Overtime, ECT has been used in the treatment of different psychiatric and some somatic conditions. Currently, ECT has been limited to fewer indications and modified so as to decrease its side effects. ECT has been widely employed in the treatment of other diseases such as obsessive compulsive disorder², postpartum psychosis³ and Parkinson’s disease with varying degree of success. According to American Psychiatric Association, ECT is widely considered as the most effective antidepressant treatment of both manic, depressed phases of bipolar disorder and included it as an optional treatment for refractory bipolar disorder⁴.⁵.

Some studies have shown that ECT is a useful treatment for a variety of complicated psychiatric conditions especially affective disorders resistant to psychotherapy, medication and other forms of treatment⁶. Electroconvulsive therapy has also been shown to reduce symptoms related with intractable depression⁷,⁸. The effectiveness of ECT in the treatment of bipolar depression has also been explained in some studies whereby it has been found to be equally effective in unipolar and bipolar depression and treatment of resistant patient⁹.¹⁰.

Dunne et al. observed that bifrontal ECT is effective in the treatment of depression to the more usual bitemporal ECT and is linked with fewer memory deficits. Concerning major depression disorder (MDD), ECT has been reported to be helpful in reducing depressive symptoms and is commonly therapeutic indicated to these particular patients. The importance of ECT in the treatment of Treatment Resistant Schizophrenia (TRS) cannot be ignored. Published reports suggest ECT to be a valuable and safe enrichment in TRS including clozapine-resistant schizophrenia¹¹,¹². The American Psychiatric Association on ECT through its task force approved ECT for Treatment-Resistant Schizophrenia¹³. Multiple published reports resolved that adjunctive ECT added to any type of antipsychotics could generate symptomatic improvement in TRS. ECT combined with all types of antipsychotics has also been indicated to be an effective treatment for schizophrenia¹⁴.¹⁵. Wei at al, in their study, observed that adjunctive ECT is normally safe and well tolerated although 16 patients complained of headache and 32 patients experienced memory impairment. Wenzheng et al. found that combined treatment of ECT and antipsychotic medication in treating refractory schizophrenia leads to improved clinical outcomes, increase the incidence of headaches and memory deficits during treatment and better overall functioning at the end of the treatment¹⁶.
II. Electroconvulsive Therapy And Neurocognitive Deficits

Major complications of electroconvulsive therapy include confusion, delirium, transient headache, muscle pain, nausea, vomiting, prolonged seizures, teeth damages and circulatory failure. During ECT application and immediately following post-ictal period benign arrhythmias occur frequently. Most adverse effects of memory deficit manifest as post ictal confusion, anterograde and/or retrograde memory amnesia, or long-term subjective memory deficit in a minority of patients. Numerous studies have also shown that post-ECT neurocognitive impairment includes; slow processing speed, verbal and working memory deficits or more widespread cognitive effects and these might be associated with a shorter duration between the last ECT session and post-treatment assessment in these reports.

However, different studies have attributed the limited utilisation of ECT to its long-lasting cognitive side effects and memory deficits with 12.4% prevalence for permanent anterograde amnesia in a community setting. Also, one study not only reported on the restricted use of ECT due to its cognitive adverse effects but also asked if these effects can be fully reversible or remain permanent. The commonest complaints from patient post-ECT includes retrograde amnesia and loss of autobiography memory. Amnesia episode may last from 1 to 6 months after the end of ECT sessions, but there is no impairment of acquisition and retention of new memories. Another author’s indicated that memory problems could be solved after a one-month intervention. Fraser et al. observed that memory deficits caused by ECT usually last for less than six months. Apart from most of the patients returning to their previous cognitive status, few still suffer from permanent drawbacks in their memory.

Some studies have demonstrated that various neurocognitive effects related to ECT mostly occur during the first three days after treatment and they consequently resolve or even improve after sometime. Mohn et al. earlier in their study observed improved neurocognitive function significantly occurs six weeks after ECT treatment. Six months after treatment Mohn and Bjørn further observed that cognitive improvement was maintained and expanded from the previous assessment at six weeks.

Short and long term memory deficits have been indicated to occur shortly and two months post-ECT respectively in patients with major depressive disorder who exhibits poor performance in stating the exact details of stories and most had difficulty in remembering stories of others compared with their personal biography. During follow-up, retrograde amnesia was discovered to be reduced after two months, but impairment in recalling the recent public events in detail persist. Autobiographical memory (memory for personal events and facts) is vital for self-definition, social interaction and as a guide for current and future events and analytical reasoning. The deficit in autobiographical memory has been indicated as the most severe cognitive side effect of ECT.

Moreover, other studies have documented the occurrence of dense retrograde amnesia with gaps in memory of autobiographical events (e.g. Vacation, illness, weddings, etc.) stretching back several years. Post-ECT euthymic bipolar disorder patients have been shown to have greater memory impairment compared to those with an assumed equal past burden of illness but without prior ECT. Elvira et al. demonstrated that ECT had a significant effect on delayed memory function in patients with major depression with melancholic features. However, four weeks after treatment discontinuation, these functions recovered. Depressive patients who underwent ECT treatment when tested 24–48hrs after the last session were found to show a decline in word fluency, immediate and delay recall of verbal material, reduced ability to discriminate between words previously heard against other words and reduction of reaction time. However, one month later, the neurocognitive deficits of these patients returned or exceeded pretreatment level. ECT combined with antidepressant during the therapy of treatment resistant depression, leads to increasing incidence of memory deficits compared to ECT alone in the weeks after treatment. Multiple studies reported on the association of ECT cognitive deficits to electrode placement and pulse stimulation. Ute et al. observed in their study that right unilateral ECT treatment was not related with any decrease in general neurocognitive function compared to the psychopharmacologic treatment of bipolar depression. Bilateral electrode (BL) placement is associated with more pronounce short term cognitive deficits than right unilateral (RUL) electrode placement. Svenja et al. revealed that non-psychotic major depression patient who underwent ECT treatment one week after the course of unilateral ECT exhibited anterograde, retrograde and subjective memory deficits more than those patients treated with repetitive transcranial magnetic stimulation (rTMS) or the control group in their study. Use of ultra brief pulse stimulation (ECT) is related with markedly decrease of the acute, short-term and long-term adverse cognitive effects of the ECT treatment.

III. Mechanism Of Action Of Neurocognitive Deficit In Ect Therapy
The essential region of the brain concerned with learning and memory is the hippocampus. Normal functions of learning and memory in the brain are maintained by the balance of neuronal transmission between the excitatory neurotransmitter glutamate and the inhibitory substance GABA. ECT treatment has been proved to induce stress leading to increased hippocampal Glu concentration, which in turn excites the ionotropic receptor GluR, therefore, inhibiting the Akt signaling pathway decreasing the activity of Akt which leads to weakening the inhibition of GSK-3β by Akt, increasing the activity of GSK-3β, increasing hippocampal protein Tau phosphorylation, decreasing axonal transport efficiency, impairing neural signal transmission thereby causing neuron apoptosis or death, leading to the learning and memory deficit. Phosphorylation of Tau protein leads to reduced axonal transport efficiency thereby impairing neural signal transmission and causing neuron apoptosis or death and eventually leading to impairment of learning and memory. Gang Liu et al proved that ECT-induced stress increases hippocampal Glu concentration and Tau protein phosphorylation leading to learning and memory impairment and is clearly associated with the current and duration of ECT. Previous studies have shown that electroconvulsive seizure for 120-180sec can lead to cognitive disorders due to pathological dysfunction of the glumatic acid (Glu) signalling system. Glu, an excitatory neurotransmitter transmits ~40% of synapses leading to oxidative stress, causing hippocampal indiscrimination’s and saturated long-term potentiation (LTP), resulting in synaptic plasticity deterioration and The Akt Pathway or PI3K-Akt Pathway, a signal transduction pathway responsible for the promotion of survival and growth in response to extracellular signals and its main protein includes PI3K (phosphatidylinositol 3-kinase) and Akt (Protein Kinase B).

IV. Prevention Of Neurocognitive Side-Effect Of Electroconvulsive Therapy

As described above, Tau protein hyperphosphorylation leads to diminishment of neurotransmitter transport and in turn causes accumulation of Glu in damaged neurons, creating cycles, increasing neuron injury and finally causing cognitive impairment. The use of 2, 6-disoproplyphenol decreases the Glu accumulation in the damaged neuron in the brain, thereby preventing cognitive impairment by antagonizing the NMD receptor. Improvement of cognitive function after ECT treatment cessation occurs through the following mechanism by:
1. Directly inducing transient neuroplastic changes in the hippocampus and other cerebral regions involved in learning and memory.
2. Indirectly via its antidepressant properties leading to increased cognitive function
3. Combination of both neuroplastic and antidepressant effect of ECT

The ability of propofol and liothyronine in preventing memory deficits after ECT treatment cannot be neglected. Numerous studies have demonstrated that propofol, an intravenous anaesthetic widely used for general anaesthesia in ECT probably reduces adverse effects of ECT on memory and cognitive function. Propofol is an intravenous anaesthetic that is metabolized quickly hence leading to early awakening. It’s a short-acting lipophilic drug that quickly crosses the blood-brain barrier with an onset of action ranging from seconds to minutes.

Butterfield et al. also reported greater reduction in post ECT cognitive impairment with propofol compared with thiopental when assessing cognitive states 5 minutes after each ECT by applying various neuropsychological tests, including immediate and delay verbal memory, confirming that propofolanaesthesia is less damaging to cognitive function when compared to older anesthetic agents such as thiopental.

Published report also revealed that propofol administered before ECT inhibited the decrease of glutamic acid in the hippocampus usually observed after ECT. Propofol has also been shown to reverse the change in hippocampal glutamate alpha-aminobutyric acid (GABA) level, and their ratio induced by electroconvulsive shock in depressed rats. It was further demonstrated that propofol reversed the elevated expression of hippocampal glutamic acid decarboxylase 65 (GAD 65) induced by electroconvulsive shock in depressed rats. GABA production pathway in the brain uses glutamate substrate and GAD as a catalyst, whereby GAD 65 is GAD catalyst. Thus explaining the protective effects of propofol.

Another study by Li et al., explained that propofol might also improve ECT-induced learning/memory impairments in depressed rats by enhancing hippocampal activation of calcium/calmodulin-dependant protein kinase II (CaMK II), a critical enzyme in the initiation and early maintenance of synaptic changes that contribute to learning and memory. Liothyronine has been reported to prevent memory deficits after ECT treatment in a patient with Major Depressive Disorder (MDD). Some studies revealed that patients receiving liothyronine had better scores on the depression and memory scores, six months post-ECT sessions. Also, another study showed that liothyronine could improve verbal learning performance and remote memory in a trial of 30 patients. Findings in a study by Arash et al. concurred with above results by showing that liothyronine improves the performance of verbal and visual memory, attention and delay recall in patients with Major Depressive Disorder undergoing ECT treatment. The mechanism of action of liothyronine is by suppression of...
Neurocognitive Effects Of Electroconvulsive Therapy In Psychiatric Disorders,......

thyrotropin releasing hormone thereby lowering the required dose of electroshock and consequently decrease the damage and adverse cognitive effects 72. Moreover, decrease in T3 level in patients receiving liothyronine leads to a temporary disruption in action cytoskeleton responsible for cells from destructive effects of convulsion in amygdala and hippocampus neurons 75. The above two mechanisms are sensitive to convulsion and play a significant role in memory and learning.

Conclusion
ECT has been shown to be important in the treatment of different psychiatric and somatic conditions. Neurocognitive deficits which occur after ECT treatment are usually reversible within six month period. Electrode placement positions also determine the extent of cognitive deficits with bilateral electrode placement associated with greater short-term deficits as compared with right unilateral electrode placement. Use of bilateral electrode placement and ultra brief pulse stimulation (ECT) should be investigated further due to their marked short and long term adverse cognitive deficits. Further research on Propofol and liothyronine use in ECT treatment should also be conducted to come up with a guideline which will incorporate either of the two as a standard treatment protocol for ECT treatment.

Disclosure Of Interest
The authors declare that there was no conflict of interest

References
Neurocognitive Effects Of Electroconvulsive Therapy In Psychiatric Disorders,...


DOI: 10.9790/0853-16047087792
www.iosrjournals.org 91 | Page
Neurocognitive Effects Of Electroconvulsive Therapy In Psychiatric Disorders,


